英夫利昔单抗治疗克罗恩病患者并发急性肾小管间质性肾炎：一例报告

Alghamdi Naif, Alshehri Fahad, Alhazza Sultan, Bhutto Fahad, Alhassan Azhari, Kechrid Mohammed, Alshehri Dhafer, Alshammari Kadi, Assiri Talal, Assiri Ohoud, Darewsh Emad, Ali Mohammed, Qadri Ruba, Alahmadi Yasser

Internal Medicine Department, Nephrology Division, Security Forces Hospital Program, Riyadh, Saudi Arabia.

Internal Medicine Department, Security Forces Hospital Program, Riyadh, Saudi Arabia.

CEN Case Rep. 2025 Apr;14(2):266-270. doi: 10.1007/s13730-024-00943-6. Epub 2024 Nov 2.

We report the case of a 39-year-old man who presented with a history of generalized fatigue, nausea, subjective fever with rigors, and renal dysfunction after receiving infliximab (IFX) therapy for Crohn's disease. A renal biopsy revealed acute tubulointerstitial nephritis (ATIN). After other causes of acute kidney injury were excluded, steroid therapy was initiated, his fever subsided, and kidney function improved. From this case report, infliximab could be a rare cause of elevated kidney function and that it should be not considered a completely safe treatment or disregarded as potential cause of ATIN.

我们报告了一例39岁男性病例，该患者在接受英夫利昔单抗（IFX）治疗克罗恩病后出现全身疲劳、恶心、伴有寒战的主观发热及肾功能障碍病史。肾活检显示为急性肾小管间质性肾炎（ATIN）。在排除急性肾损伤的其他病因后，开始使用类固醇治疗，其发热消退，肾功能改善。从该病例报告来看，英夫利昔单抗可能是肾功能升高的罕见原因，不应被视为完全安全的治疗方法，也不能忽视其作为ATIN潜在病因的可能性。